Stem Cell Transplant and Cellular Therapies Symposium: Improving Access and Equity to Evolving Therapies

October 1, 2021

 

Please Note: This is a virtual event via Accelevents

https://www.accelevents.com/e/dfcisymposium2021

Description

Join clinical leaders from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Boston Children’s Hospital in the Transplant & Cell Therapies Annual Symposium: Improving Access and Equity to Evolving Therapies

Target Audience

This activity is intended for local referring providers, nurses, PAs, pharmacists, payer representatives, case managers.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Demonstrate comprehension of the referral process and care coordination between the community oncologist and the transplant team, including the pre-transplant workup process.
  2. Identify common and uncommon post-treatment toxicities post-treatment and differentiate between various common, chronic, and advanced infections post-treatment.
  3. Demonstrate comprehension of the use of haploidentical transplantation and its practicality.
  4. Review other non-infectious concerns that may present during short-term and long-term recovery from treatment.
  5. Categorize common toxicities during CAR T-cell treatment 6. Discuss latest therapies in research and clinical practice

Additional Information

Provided by: 

Dana-Farber Cancer Institute and Mass General Brigham

 

 

 

Course summary
Available credit: 
  • 4.00 AMA PRA Category 1 Credit™
  • 3.83 Nursing Contact Hours
  • 4.00 Participation
Course opens: 
07/26/2021
Course expires: 
11/01/2021
Event starts: 
10/01/2021 - 9:30am EDT
Event ends: 
10/01/2021 - 1:50pm EDT
Cost:
$25.00
Add to calendar: 

Dana-Farber Cancer Institute
Boston, MA
United States

Corey Cutler, MD, MPH, FRCPC - Course Director

Medical Director, Division of Transplant and Cell Therapies,
Dana-Farber Cancer Institute

Abigail Ciampa, NP

Nurse Practitioner, Adult Survivorship Clinic,
Dana-Farber Cancer Institute

Joseph H. Antin, MD

Jock and Bunny Adams Chair in Hematology,
Professor of Medicine, Harvard Medical School;
Dana-Farber Cancer Institute

Clifton Mo, MD

Clinical Director, Multiple Myeloma Division,
Dana-Farber Cancer Institute

Caron Jacobson, MD

Medical Director, Immune Effector Cell Therapy Program,
Dana-Farber Cancer Institute

Rizwan Romee, MD

Director, Haploidentical Transplantation Program,
Dana-Farber Cancer Institute

Dana Yoo, PhD

Director of Innovation,
National Marrow Donor Program/ Be The Match

Desiree Otenti, NP

Sr. Director of Medical Policy,
Blue Cross Blue Shield MA

Ludmila Svoboda, RN, BSN, MA, OCN

Program Nurse, Cancer Care Equity Program,
Dana-Farber Cancer Institute

Leslie Lehmann, MD

Associate Program Director, Fellowship and Training and Quality ,
Pediatric Hematopoietic Stem Cell Transplant Program,
Dana-Farber Cancer Institute/Boston Children’s Hospital

Sarah Hammond, MD

Director, Hematology/Oncology Infectious Disease,
Massachusetts General Hospital 

Kecia Boyd, DNP, RN, NEA-BC, AOCNS, BMTCN

Director, Nursing and Patient Care Services Inclusion, Diversity, and Equity,
Dana-Farber Cancer Institute 

Amy Emmert

Executive Director for External Affairs, Division of Transplant and Cell Therapies Service Line,
Dana-Farber Cancer Institute 

Kidest Mequanent

Senior Program Manager, Cell Therapies and Shared Care,
Dana-Farber Cancer Institute 

Julie Porter

Vice President of Cellular Therapy Operations,
Dana-Farber Cancer Institute 

Mass General Brigham is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Mass General Brigham designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing

Credit Designation Statement
3.83 Contact Hour(s) of Nursing Continuing Professional Development (NCPD), will be awarded for attending the presentation in its entirety and completing an evaluation.

Approval Statement
Dana-Farber Cancer Institute is approved as a provider of nursing continuing professional development by the American Nurses Association Massachusetts, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

 

Available Credit

  • 4.00 AMA PRA Category 1 Credit™
  • 3.83 Nursing Contact Hours
  • 4.00 Participation

Price

Cost:
$25.00
Please login or register to take this course.

If you are having difficulty registering for the event, please reach out to the Mass General Brigham Office of Continuing Professional Development at partnerscpd@partners.org

Cancellation Policy:

Registrations cancelled on or before September 17, 2021 will be refunded, less a $15 administrative fee. Registrations cancelled after September 17, 2021 will not be refunded.

Contact partnerscpd@partners.org if you require assistance in cancelling your online registration.